NCT04504331 2026-02-12
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Phase 1 Terminated
Stanford University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Southern California
Stanford University